{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:47:03Z","timestamp":1791316023452,"version":"4.3.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/mp.2016.6","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T09:39:32Z","timestamp":1456220372000},"page":"1717-1725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics"],"prefix":"10.1038","volume":"21","author":[{"given":"M","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Neavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Biernacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hall-Flavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W V","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Skime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G D","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Batzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kalari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Matson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S S","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mushiroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Weinshilboum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"BFmp20166_CR1","first-page":"21","volume":"420","author":"J Alonso","year":"2004","unstructured":"Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21\u201327.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BFmp20166_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9: 90.","journal-title":"BMC Med"},{"key":"BFmp20166_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/wps.20128","volume":"13","author":"E Chesney","year":"2014","unstructured":"Chesney E, Goodwin GM, Fazel S . Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153\u2013160.","journal-title":"World Psychiatry"},{"key":"BFmp20166_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1017\/S1092852914000613","volume":"19","author":"DA Morrissette","year":"2014","unstructured":"Morrissette DA, Stahl SM . Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectr 2014; 19: 54\u201368.","journal-title":"CNS Spectr"},{"issue":"4 Suppl 1","key":"BFmp20166_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/S1092852900028595","volume":"7","author":"JM Gorman","year":"2002","unstructured":"Gorman JM, Korotzer A, Su G . Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7 (4 Suppl 1): 40\u201344.","journal-title":"CNS Spectr"},{"key":"BFmp20166_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1755-5949.2010.00146.x","volume":"16","author":"M El Mansari","year":"2010","unstructured":"El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P . Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010; 16: e1\u201317.","journal-title":"CNS Neurosci Ther"},{"key":"BFmp20166_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clinthera.2011.11.024","volume":"34","author":"HD Anderson","year":"2012","unstructured":"Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ . Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther 2012; 34: 113\u2013123.","journal-title":"Clin Ther"},{"key":"BFmp20166_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/pds.1541","volume":"17","author":"AJ Smith","year":"2008","unstructured":"Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE . A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008; 17: 697\u2013706.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"BFmp20166_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28\u201340.","journal-title":"Am J Psychiatry"},{"key":"BFmp20166_CR10","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1038\/tp.2015.47","volume":"5","author":"JM Biernacka","year":"2015","unstructured":"Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 2015; 5: e553.","journal-title":"Transl Psychiatry"},{"key":"BFmp20166_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/tpj.2012.32","volume":"13","author":"Y Ji","year":"2013","unstructured":"Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 2013; 13: 456\u2013463.","journal-title":"Pharmacogenomics J"},{"key":"BFmp20166_CR12","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1176\/appi.ajp.157.10.1552","volume":"157","author":"PF Sullivan","year":"2000","unstructured":"Sullivan PF, Neale MC, Kendler KS . Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552\u20131562.","journal-title":"Am J Psychiatry"},{"key":"BFmp20166_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/archpsyc.56.6.557","volume":"56","author":"LJ Bierut","year":"1999","unstructured":"Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry 1999; 56: 557\u2013563.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp20166_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/archpsyc.1996.01830020047006","volume":"53","author":"P McGuffin","year":"1996","unstructured":"McGuffin P, Katz R, Watkins S, Rutherford J . A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry 1996; 53: 129\u2013136.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp20166_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archpsyc.1993.01820230054003","volume":"50","author":"KS Kendler","year":"1993","unstructured":"Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ . The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch Gen Psychiatry 1993; 50: 863\u2013870.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp20166_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.pnpbp.2005.03.013","volume":"29","author":"A Serretti","year":"2005","unstructured":"Serretti A, Benedetti F, Zanardi R, Smeraldi E . The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1074\u20131084.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20166_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1517\/17425255.2014.928693","volume":"10","author":"C Fabbri","year":"2014","unstructured":"Fabbri C, Minarini A, Niitsu T, Serretti A . Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Exp Opin Drug Metab Toxicol 2014; 10: 1093\u20131118.","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"BFmp20166_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1176\/ps.2009.60.11.1446","volume":"60","author":"G Laje","year":"2009","unstructured":"Laje G, Perlis RH, Rush AJ, McMahon FJ . Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 2009; 60: 1446\u20131457.","journal-title":"Psychiatr Serv"},{"key":"BFmp20166_CR19","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1038\/tp.2015.127","volume":"5","author":"W Myung","year":"2015","unstructured":"Myung W, Kim J, Lim SW, Shim S, Won HH, Kim S et al. A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry 2015; 5: e633.","journal-title":"Transl Psychiatry"},{"key":"BFmp20166_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","volume":"45","author":"T Niitsu","year":"2013","unstructured":"Niitsu T, Fabbri C, Bentini F, Serretti A . Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183\u2013194.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20166_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1176\/appi.ajp.2012.12020237","volume":"170","author":"GENDEP Investigators, MARS Investigators, STAR*D Investigators.","year":"2013","unstructured":"GENDEP Investigators, MARS Investigators, STAR*D Investigators.. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170: 207\u2013217.","journal-title":"Am J Psychiatry"},{"key":"BFmp20166_CR22","doi-asserted-by":"publisher","first-page":"e1001326","DOI":"10.1371\/journal.pmed.1001326","volume":"9","author":"KE Tansey","year":"2012","unstructured":"Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9: e1001326.","journal-title":"PLoS Med"},{"key":"BFmp20166_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1176\/appi.ajp.2009.09070932","volume":"167","author":"R Uher","year":"2010","unstructured":"Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555\u2013564.","journal-title":"Am J Psychiatry"},{"key":"BFmp20166_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.biopsych.2009.08.029","volume":"67","author":"HA Garriock","year":"2010","unstructured":"Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133\u2013138.","journal-title":"Biol Psychiatry"},{"key":"BFmp20166_CR25","first-page":"87","volume":"14","author":"S Weizman","year":"2012","unstructured":"Weizman S, Gonda X, Dome P, Faludi G . Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung 2012; 14: 87\u2013101.","journal-title":"Neuropsychopharmacol Hung"},{"key":"BFmp20166_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s11920-015-0594-9","volume":"17","author":"C Fabbri","year":"2015","unstructured":"Fabbri C, Serretti A . Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep 2015; 17: 594.","journal-title":"Curr Psychiatry Rep"},{"key":"BFmp20166_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/YCO.0000000000000023","volume":"27","author":"AB Singh","year":"2014","unstructured":"Singh AB, Bousman CA, Ng C, Berk M . Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014; 27: 43\u201351.","journal-title":"Curr Opin Psychiatry"},{"key":"BFmp20166_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/clpt.2010.250","volume":"89","author":"Y Ji","year":"2011","unstructured":"Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram\/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011; 89: 97\u2013104.","journal-title":"Clin Pharmacol Ther"},{"key":"BFmp20166_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/FPC.0b013e32835001c9","volume":"22","author":"R Abo","year":"2012","unstructured":"Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 2012; 22: 247\u2013253.","journal-title":"Pharmacogenet Genomics"},{"key":"BFmp20166_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/092986713804806621","volume":"20","author":"MS Monteiro","year":"2013","unstructured":"Monteiro MS, Carvalho M, Bastos ML, Guedes de Pinho P . Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 2013; 20: 257\u2013271.","journal-title":"Curr Med Chem"},{"key":"BFmp20166_CR31","doi-asserted-by":"publisher","first-page":"e68283","DOI":"10.1371\/journal.pone.0068283","volume":"8","author":"H Zhu","year":"2013","unstructured":"Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PloS One 2013; 8: e68283.","journal-title":"PloS One"},{"key":"BFmp20166_CR32","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1038\/tp.2012.142","volume":"3","author":"R Kaddurah-Daouk","year":"2013","unstructured":"Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry 2013; 3: e223.","journal-title":"Transl Psychiatry"},{"key":"BFmp20166_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cpt.134","volume":"98","author":"R Kaddurah-Daouk","year":"2015","unstructured":"Kaddurah-Daouk R, Weinshilboum R . Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 2015; 98: 71\u201375.","journal-title":"Clin Pharmacol Ther"},{"key":"BFmp20166_CR34","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/psp.2014.22","volume":"3","author":"S Ellero-Simatos","year":"2014","unstructured":"Ellero-Simatos S, Lewis JP, Georgiades A, Yerges-Armstrong LM, Beitelshees AL, Horenstein RB et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol 2014; 3: e125.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFmp20166_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/clpt.2013.119","volume":"94","author":"LM Yerges-Armstrong","year":"2013","unstructured":"Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Thera 2013; 94: 525\u2013532.","journal-title":"Clin Pharmacol Thera"},{"key":"BFmp20166_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/JCP.0000000000000099","volume":"34","author":"DA Mrazek","year":"2014","unstructured":"Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 2014; 34: 313\u2013317.","journal-title":"J Clin Psychopharmacol"},{"key":"BFmp20166_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bcp.12348","volume":"78","author":"Y Ji","year":"2014","unstructured":"Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 2014; 78: 373\u2013383.","journal-title":"Br J Clin Pharmacol"},{"key":"BFmp20166_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GTEx Consortium","year":"2013","unstructured":"GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580\u2013585.","journal-title":"Nat Genet"},{"key":"BFmp20166_CR39","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/clinchem\/30.9.1477","volume":"30","author":"WR Matson","year":"1984","unstructured":"Matson WR, Langlais P, Volicer L, Gamache PH, Bird E, Mark KA . n-Electrode three-dimensional liquid chromatography with electrochemical detection for determination of neurotransmitters. Clin Chem 1984; 30: 1477\u20131488.","journal-title":"Clin Chem"},{"key":"BFmp20166_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1210\/me.2012-1397","volume":"27","author":"M Liu","year":"2013","unstructured":"Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M et al. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol 2013; 27: 657\u2013670.","journal-title":"Mol Endocrinol"},{"key":"BFmp20166_CR41","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1101\/gr.107672.110","volume":"20","author":"N Niu","year":"2010","unstructured":"Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M et al. Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010; 20: 1482\u20131492.","journal-title":"Genome Res"},{"key":"BFmp20166_CR42","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1158\/0008-5472.CAN-08-0405","volume":"68","author":"L Li","year":"2008","unstructured":"Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008; 68: 7050\u20137058.","journal-title":"Cancer Res"},{"key":"BFmp20166_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-13-0038","volume":"3","author":"JN Ingle","year":"2013","unstructured":"Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 2013; 3: 812\u2013825.","journal-title":"Cancer Discov"},{"key":"BFmp20166_CR44","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1210\/me.2014-1147","volume":"28","author":"M Liu","year":"2014","unstructured":"Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A et al. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol 2014; 28: 1740\u20131751.","journal-title":"Mol Endocrinol"},{"key":"BFmp20166_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"GR Abecasis","year":"2012","unstructured":"Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56\u201365.","journal-title":"Nature"},{"key":"BFmp20166_CR46","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1097\/00001756-200009280-00027","volume":"11","author":"C Garcia-Frigola","year":"2000","unstructured":"Garcia-Frigola C, Burgaya F, Calbet M, de Lecea L, Soriano E . Mouse Tspan-5, a member of the tetraspanin superfamily, is highly expressed in brain cortical structures. Neuroreport 2000; 11: 3181\u20133185.","journal-title":"Neuroreport"},{"key":"BFmp20166_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0925-4773(01)00436-1","volume":"106","author":"C Garcia-Frigola","year":"2001","unstructured":"Garcia-Frigola C, Burgaya F, de Lecea L, Soriano E . Pattern of expression of the tetraspanin Tspan-5 during brain development in the mouse. Mech Dev 2001; 106: 207\u2013212.","journal-title":"Mech Dev"},{"key":"BFmp20166_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/cne.20439","volume":"483","author":"H Juenger","year":"2005","unstructured":"Juenger H, Holst MI, Duffe K, Jankowski J, Baader SL . Tetraspanin-5 (Tm4sf9) mRNA expression parallels neuronal maturation in the cerebellum of normal and L7En-2 transgenic mice. J Comp Neurol 2005; 483: 318\u2013328.","journal-title":"J Comp Neurol"},{"key":"BFmp20166_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0167-4781(98)00087-6","volume":"1399","author":"SC Todd","year":"1998","unstructured":"Todd SC, Doctor VS, Levy S . Sequences and expression of six new members of the tetraspanin\/TM4SF family. Biochim Biophys Acta 1998; 1399: 101\u2013104.","journal-title":"Biochim Biophys Acta"},{"key":"BFmp20166_CR50","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/nn.3801","volume":"17","author":"A Ramasamy","year":"2014","unstructured":"Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci 2014; 17: 1418\u20131428.","journal-title":"Nat Neurosci"},{"key":"BFmp20166_CR51","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ng.2756","volume":"45","author":"HJ Westra","year":"2013","unstructured":"Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013; 45: 1238\u20131243.","journal-title":"Nat Genet"},{"key":"BFmp20166_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.clpt.2003.12.002","volume":"75","author":"R Weinshilboum","year":"2004","unstructured":"Weinshilboum R, Wang L . Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 2004; 75: 253\u2013258.","journal-title":"Clin Pharmacol Ther"},{"key":"BFmp20166_CR53","doi-asserted-by":"publisher","first-page":"9394","DOI":"10.1073\/pnas.0502352102","volume":"102","author":"L Wang","year":"2005","unstructured":"Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM . Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 2005; 102: 9394\u20139399.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp20166_CR54","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/FPC.0b013e328313e03f","volume":"18","author":"F Li","year":"2008","unstructured":"Li F, Wang L, Burgess RJ, Weinshilboum RM . Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics 2008; 18: 1083\u20131094.","journal-title":"Pharmacogenet Genomics"},{"key":"BFmp20166_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200309000-00004","volume":"13","author":"L Wang","year":"2003","unstructured":"Wang L, Sullivan W, Toft D, Weinshilboum R . Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003; 13: 555\u2013564.","journal-title":"Pharmacogenetics"},{"key":"BFmp20166_CR56","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1073\/pnas.1001647107","volume":"107","author":"CD Dunn","year":"2010","unstructured":"Dunn CD, Sulis ML, Ferrando AA, Greenwald I . A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proc Natl Acad Sci USA 2010; 107: 5907\u20135912.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp20166_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1083\/jcb.201201133","volume":"199","author":"E Dornier","year":"2012","unstructured":"Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, Mauduit P et al. TspanC8 tetraspanins regulate ADAM10\/Kuzbanian trafficking and promote Notch activation in flies and mammals. J Cell Biol 2012; 199: 481\u2013496.","journal-title":"J Cell Biol"},{"key":"BFmp20166_CR58","doi-asserted-by":"publisher","first-page":"39753","DOI":"10.1074\/jbc.M112.416503","volume":"287","author":"EJ Haining","year":"2012","unstructured":"Haining EJ, Yang J, Bailey RL, Khan K, Collier R, Tsai S et al. The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J Biol Chem 2012; 287: 39753\u201339765.","journal-title":"J Biol Chem"},{"key":"BFmp20166_CR59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2332\/allergolint.O-07-488","volume":"56","author":"K Iwai","year":"2007","unstructured":"Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y . Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of Tspan-5 and NET-6 during osteoclastogenesis. Allergol Int 2007; 56: 457\u2013463.","journal-title":"Allergol Int"},{"key":"BFmp20166_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00223-014-9883-2","volume":"95","author":"J Zhou","year":"2014","unstructured":"Zhou J, Fujiwara T, Ye S, Li X, Zhao H . Downregulation of Notch modulators, tetraspanin 5 and 10, inhibits osteoclastogenesis in vitro. Calcif Tissue Int 2014; 95: 209\u2013217.","journal-title":"Calcif Tissue Int"},{"issue":"Pt 18","key":"BFmp20166_CR61","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1242\/jcs.102152","volume":"125","author":"M Shi","year":"2012","unstructured":"Shi M, Hu ZL, Zheng MH, Song NN, Huang Y, Zhao G et al. Notch-Rbpj signaling is required for the development of noradrenergic neurons in the mouse locus coeruleus. J Cell Sci 2012; 125 (Pt 18): 4320\u20134332.","journal-title":"J Cell Sci"},{"key":"BFmp20166_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s002130050924","volume":"143","author":"JC Alvarez","year":"1999","unstructured":"Alvarez JC, Gluck N, Fallet A, Gregoire A, Chevalier JF, Advenier C et al. Plasma serotonin level after 1day of fluoxetine treatment: a biological predictor for antidepressant response? Psychopharmacology (Berl) 1999; 143: 97\u2013101.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFmp20166_CR63","first-page":"4","volume":"29","author":"J Moreno","year":"2006","unstructured":"Moreno J, Campos MG, Lara C, Lopez G, Pavon L, Hernandez ME et al. Tryptophan and serotonin in blood and platelets of depressed patients: Effect of an antidepressant treatment. Salud Mental 2006; 29: 4.","journal-title":"Salud Mental"},{"key":"BFmp20166_CR64","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0192-0561(99)00035-1","volume":"21","author":"M Urbina","year":"1999","unstructured":"Urbina M, Pineda S, Pinango L, Carreira I, Lima L . [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 1999; 21: 631\u2013646.","journal-title":"Int J Immunopharmacol"},{"key":"BFmp20166_CR65","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0278-5846(90)90051-H","volume":"14","author":"SP Tyrer","year":"1990","unstructured":"Tyrer SP, Marshall EF, Griffiths HW . The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 797\u2013805.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20166_CR66","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.euroneuro.2008.08.001","volume":"18","author":"ME Hernandez","year":"2008","unstructured":"Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I et al. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 917\u2013924.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFmp20166_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00004714-200204000-00005","volume":"22","author":"P Blardi","year":"2002","unstructured":"Blardi P, De Lalla A, Leo A, Auteri A, Iapichino S, Di Muro A et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22: 131\u2013136.","journal-title":"J Clin Psychopharmacol"},{"key":"BFmp20166_CR68","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/01.jcp.0000138765.08235.46","volume":"24","author":"N Kotzailias","year":"2004","unstructured":"Kotzailias N, Marker M, Jilma B . Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2004; 24: 536\u2013539.","journal-title":"J Clin Psychopharmacol"},{"key":"BFmp20166_CR69","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/01.jcp.0000161500.58266.90","volume":"25","author":"P Blardi","year":"2005","unstructured":"Blardi P, de Lalla A, Urso R, Auteri A, Dell'Erba A, Bossini L et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol 2005; 25: 262\u2013266.","journal-title":"J Clin Psychopharmacol"},{"key":"BFmp20166_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1096\/fasebj.11.6.9194523","volume":"11","author":"HT Maecker","year":"1997","unstructured":"Maecker HT, Todd SC, Levy S . The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11: 428\u2013442.","journal-title":"FASEB J"},{"key":"BFmp20166_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0161-5890(01)00100-6","volume":"38","author":"M Kurita-Taniguchi","year":"2002","unstructured":"Kurita-Taniguchi M, Hazeki K, Murabayashi N, Fukui A, Tsuji S, Matsumoto M et al. Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF. Mol Immunol 2002; 38: 689\u2013700.","journal-title":"Mol Immunol"},{"key":"BFmp20166_CR72","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.1074\/jbc.M008650200","volume":"276","author":"C Claas","year":"2001","unstructured":"Claas C, Stipp CS, Hemler ME . Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001; 276: 7974\u20137984.","journal-title":"J Biol Chem"},{"key":"BFmp20166_CR73","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1038\/sj.emboj.7600349","volume":"23","author":"RA Kovall","year":"2004","unstructured":"Kovall RA, Hendrickson WA . Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA. EMBO J 2004; 23: 3441\u20133451.","journal-title":"EMBO J"},{"key":"BFmp20166_CR74","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-009-8668-7","volume":"66","author":"T Borggrefe","year":"2009","unstructured":"Borggrefe T, Oswald F . The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66: 1631\u20131646.","journal-title":"Cell Mol Life Sci"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/mp20166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mp20166","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mp20166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:16:42Z","timestamp":1684433802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp20166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFmp20166"],"URL":"https:\/\/doi.org\/10.1038\/mp.2016.6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]},"assertion":[{"value":"4 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}